🔴 Telix Pharmaceuticals is trading 11.71% down today after announcing US$1.65 billion ITM acquisition

Telix Pharmaceuticals is trading 11.71% down at A$15.76 after announcing a proposed acquisition of Germany’s ITM Isotope Technologies Munich.

• Reuters reported shares fell nearly 6% in early trading after the deal was announced.
• The US$1.65 billion upfront deal includes approximately US$1.25 billion in newly issued Telix shares, raising investor concerns about dilution and execution risk.
• It could reach US$2.35 billion with milestone payments and remains subject to shareholder and regulatory approvals.